The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 304
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 78
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.Sumanta Kumar Pal, Laurence Albigès, Filippo de Braud et al.|Journal of Clinical Oncology|2024Cited by 9